Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.
Breast Cancer|Metastasis
DRUG: Capecitabine and Bevacizumab
Time to treatment progression, followed until death, average 5 years
overall response rate in patients with measurable disease at baseline, average 5 years|safety and tolerability, average 5 years|Clinical benefit (complete response, partial response and stable disease) in patients with measurable disease at baseline, average 5 years|progression-free survival, average 5 years
This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.